{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T00:48:45Z","timestamp":1791679725542,"version":"4.3.4"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T00:00:00Z","timestamp":1791676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T00:00:00Z","timestamp":1791676800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"DOI":"10.1007\/s10620-026-10273-5","type":"journal-article","created":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T00:10:16Z","timestamp":1791677416000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy of Tenapanor in Patients With or Without Prior Use of IBS-C Prescription Medications: A Post-hoc Analysis of Phase 3 Clinical Trials"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3611-8628","authenticated-orcid":false,"given":"Eric","family":"Shah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2778-0786","authenticated-orcid":false,"given":"Brian","family":"Lacy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-4286-8015","authenticated-orcid":false,"given":"Laura","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-0238-4515","authenticated-orcid":false,"given":"Yang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-8356-876X","authenticated-orcid":false,"given":"Suling","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-9620-7580","authenticated-orcid":false,"given":"Susan","family":"Edelstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9371-391X","authenticated-orcid":false,"given":"David P.","family":"Rosenbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,11]]},"reference":[{"key":"10273_CR1","unstructured":"IBSRELA (tenapanor). Prescribing Information. Waltman, MA: Ardelyx, Inc.; 2025. Available at: https:\/\/ardelyx.com\/wp-content\/uploads\/2021\/11\/IBSRELA-Prescribing-Information-1.pdf."},{"key":"10273_CR2","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s40261-017-0614-0","volume":"38","author":"DP Rosenbaum","year":"2018","unstructured":"Rosenbaum DP, Yan A, Jacobs JW. pharmacodynamics, safety, and tolerability of the NHE3 inhibitor tenapanor: two trials in healthy volunteers. Clin Drug Investig. 2018;38:341\u2013351. https:\/\/doi.org\/10.1007\/s40261-017-0614-0.","journal-title":"Clin Drug Investig."},{"key":"10273_CR3","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1007\/s10157-016-1302-8","volume":"21","author":"S Johansson","year":"2017","unstructured":"Johansson S, Rosenbaum DP, Knutsson M, Leonsson-Zachrisson M. A Phase 1 study of the safety, tolerability, pharmacodynamics, and pharmacokinetics of tenapanor in healthy Japanese volunteers. Clin Exp Nephrol. 2017;21:407\u2013416. https:\/\/doi.org\/10.1007\/s10157-016-1302-8.","journal-title":"Clin Exp Nephrol."},{"key":"10273_CR4","doi-asserted-by":"publisher","first-page":"227ra236","DOI":"10.1126\/scitranslmed.3007790","volume":"6","author":"AG Spencer","year":"2014","unstructured":"Spencer AG, Labonte ED, Rosenbaum DP, Plato CF, Carreras CW, Leadbetter MR et al. Intestinal inhibition of the Na+\/H+ exchanger 3 prevents cardiorenal damage in rats and inhibits Na+ uptake in humans. Sci Transl Med. 2014;6:227ra236. https:\/\/doi.org\/10.1126\/scitranslmed.3007790.","journal-title":"Sci Transl Med."},{"key":"10273_CR5","doi-asserted-by":"publisher","first-page":"87","DOI":"10.2147\/CEG.S454526","volume":"17","author":"P Singh","year":"2024","unstructured":"Singh P, Sayuk GS, Rosenbaum DP, Edelstein S, Kozuka K, Chang L. An overview of the effects of tenapanor on visceral hypersensitivity in the treatment of irritable bowel syndrome with constipation. Clin Exp Gastroenterol. 2024;17:87\u201396. https:\/\/doi.org\/10.2147\/CEG.S454526.","journal-title":"Clin Exp Gastroenterol."},{"key":"10273_CR6","doi-asserted-by":"publisher","first-page":"281","DOI":"10.14309\/ajg.0000000000000516","volume":"115","author":"WD Chey","year":"2020","unstructured":"Chey WD, Lembo AJ, Rosenbaum DP. Efficacy of tenapanor in treating patients with irritable bowel syndrome with constipation: a 12-week, placebo-controlled phase 3 trial (T3MPO-1). Am J Gastroenterol. 2020;115:281\u2013293. https:\/\/doi.org\/10.14309\/ajg.0000000000000516.","journal-title":"Am J Gastroenterol."},{"key":"10273_CR7","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.14309\/ajg.0000000000001056","volume":"116","author":"WD Chey","year":"2021","unstructured":"Chey WD, Lembo AJ, Yang Y, Rosenbaum DP. Efficacy of tenapanor in treating patients with irritable bowel syndrome with constipation: a 26-week, placebo-controlled phase 3 trial (T3MPO-2). Am J Gastroenterol. 2021;116:1294\u20131303. https:\/\/doi.org\/10.14309\/ajg.0000000000001056.","journal-title":"Am J Gastroenterol."},{"key":"10273_CR8","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1007\/s10620-021-06963-x","volume":"67","author":"ED Shah","year":"2022","unstructured":"Shah ED, Brenner DM, Chen VL. Baseline predictors of discontinuation of prescription drug therapy for IBS-C: cohort analysis at an integrated healthcare system. Dig Dis Sci. 2022;67:1213\u20131221. https:\/\/doi.org\/10.1007\/s10620-021-06963-x.","journal-title":"Dig Dis Sci."},{"key":"10273_CR9","first-page":"237","volume":"15","author":"DA Drossman","year":"2006","unstructured":"Drossman DA, Dumitrascu DL. Rome III: New standard for functional gastrointestinal disorders. J Gastrointestin Liver Dis. 2006;15:237\u2013241.","journal-title":"J Gastrointestin Liver Dis."},{"key":"10273_CR10","doi-asserted-by":"publisher","unstructured":"Brenner DM, Sayuk GS, Cash BD, Harris LA, Ahuja NK, Deutsch JK, Yang Y, Zhao S, Rosenbaum DP, Lembo AJ. Tenapanor Improves Abdominal Symptoms Irrespective of Changes in Complete Spontaneous Bowel Movement Frequency in Adults with Irritable Bowel Syndrome with Constipation. Dig Dis. 2025;43(2):146\u2013157. https:\/\/doi.org\/10.1159\/000543166. PMID: 39701047; PMCID: PMC11965839.","DOI":"10.1159\/000543166"},{"key":"10273_CR11","doi-asserted-by":"publisher","first-page":"558","DOI":"10.5056\/jnm16001","volume":"22","author":"MH Farzaei","year":"2016","unstructured":"Farzaei MH, Bahramsoltani R, Abdollahi M, Rahimi R. The role of visceral hypersensitivity in irritable bowel syndrome: pharmacological targets and novel treatments. J Neurogastroenterol Motil. 2016;22:558\u2013574. https:\/\/doi.org\/10.5056\/jnm16001.","journal-title":"J Neurogastroenterol Motil."},{"key":"10273_CR12","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1146\/annurev-physiol-020518-114525","volume":"81","author":"L Grundy","year":"2019","unstructured":"Grundy L, Erickson A, Brierley SM. Visceral pain. Annu Rev Physiol. 2019;81:261\u2013284. https:\/\/doi.org\/10.1146\/annurev-physiol-020518-114525.","journal-title":"Annu Rev Physiol."},{"key":"10273_CR13","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s12876-019-0985-1","volume":"19","author":"J Tack","year":"2019","unstructured":"Tack J, Stanghellini V, Mearin F, Yiannakou Y, Layer P, Coffin B et al. Economic burden of moderate to severe irritable bowel syndrome with constipation in six European countries. BMC Gastroenterol. 2019;19:69. https:\/\/doi.org\/10.1186\/s12876-019-0985-1.","journal-title":"BMC Gastroenterol."}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-026-10273-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10620-026-10273-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-026-10273-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T00:10:22Z","timestamp":1791677422000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10620-026-10273-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,11]]},"references-count":13,"alternative-id":["10273"],"URL":"https:\/\/doi.org\/10.1007\/s10620-026-10273-5","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,11]]},"assertion":[{"value":"15 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Eric Shah has served as a consultant for Ardelyx, Inc., Laborie, Mylan, Neuraxis, Phathom, Salix, Sanofi, Regeneron, and Takeda. Brian Lacy is a consultant for Allakos, Allergan, Ironwood, Salix, and Viver. Yang Yang, Suling Zhao,\u00a0and Susan Edelstein are employees of Ardelyx, Inc.\u00a0Laura Williams and David Rosenbaum were employees of Ardelyx, Inc. at the time of this study.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The trials were conducted in accordance with the Declaration of Helsinki, Good Clinical Practice Guidelines, and all applicable local laws and regulations. All participating sites obtained independent ethics committee\/institutional review board approval. All patients provided written informed consent to participate in the study.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}